Transmission:

Aerosinia Pneumovirus (APV) primarily spreads through respiratory droplets when an infected person coughs, sneezes, talks, or breathes. The virus can also be transmitted by touching surfaces contaminated with the virus and then touching the face, particularly the mouth, nose, or eyes. Additionally, APV is known to remain airborne for extended periods, increasing the risk of transmission in enclosed and poorly ventilated spaces.

Infection Rate:

APV has a high basic reproduction number (R0), estimated to be around 4.5, indicating that, on average, one infected individual can spread the virus to 4.5 other people in a susceptible population. This rate is slightly higher than that of the original strain of COVID-19, making APV highly contagious and capable of causing rapid outbreaks.

Morbidity:

The morbidity associated with APV includes a wide range of symptoms, from mild to severe. Common symptoms include fever, cough, shortness of breath, fatigue, and muscle aches. Some patients may also experience gastrointestinal symptoms such as nausea and diarrhea. Severe cases can lead to pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. Approximately 15-20% of infected individuals may require hospitalization, with severe cases predominantly occurring in older adults and those with underlying health conditions.

Mortality:

The case fatality rate (CFR) of APV is estimated to be around 2.5%, similar to that of the early strains of COVID-19. Mortality is higher among elderly individuals and those with comorbidities such as cardiovascular disease, diabetes, chronic respiratory disease, and compromised immune systems. However, with timely medical intervention and supportive care, the survival rate improves significantly.

Comparisons to COVID-19

• Transmission: Both APV and COVID-19 spread via respiratory droplets and contaminated surfaces, but APV’s ability to remain airborne for longer periods increases its transmission potential, particularly in closed environments.
• Infection Rate: APV has a slightly higher R0 of 4.5 compared to COVID-19’s original R0 of around 3.0, indicating a more rapid spread.
• Morbidity: The morbidity profiles of APV and COVID-19 are similar, with both viruses causing a range of respiratory and systemic symptoms, though APV may lead to a higher percentage of severe cases requiring hospitalization.
• Mortality: The CFR of APV is comparable to early COVID-19 strains at 2.5%, with a similar demographic at higher risk of severe outcomes and death.